New Top Exec Reshuffle To Steer OGT Down Dx Path

Oxford Gene Technology has appointed its former head of R&D, John Anson, as CEO and brought in a new head of regulatory affairs, Paul Kenny, as the company shifts resources to the molecular diagnostics market.

UK specialist in genomic analysis and next-generation sequencing specialist Oxford Gene Technology Ltd. has promoted John Anson, its former EVP of R&D who has been at the company since 2006, to the role of CEO.

Anson takes over from Mike Evans, who has led the firm since 2005 and spearheaded its transformation from a microarray...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from In Vitro Diagnostics

More from Diagnostics

Siemens Healthineers Mitigates Headwinds With ‘Value-Add Structural Changes’

 

Siemens Healthineers anticipates €400m-€500m tariff impact by 2026 but says it will mitigate losses through structural changes and pricing. Despite a revenue decline in diagnostics due to China’s VBP, diagnostics transformation activities, including cutting product, were “successful."

Biostate AI Builds Global RNA-AI Pipeline With $12M Boost, Ventures In China And India

 
• By 

Biostate AI has set up an Indian subsidiary, Bayosthiti, to develop cancer and cardiac diagnostics with local hospitals. This follows a joint venture with China's Kindstar Global and mirrors Biostate’s US collaboration with Mass General Brigham to build AI models for melanoma.

Bipartisan Senate Bill Would Give Patients ‘True Price Tag’ Prior To Care

 

Pending legislation seeks to address what the sponsors argue is a lack of transparency in medical billing. If enacted, the bill would provide patients with the costs of procedures and medications before receiving them. A data collection expert discusses what the bill could mean for patients.